REG - Porvair PLC - Board Changes

PorvairAnnouncement

25/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250925:nRSY6929Aa&default-theme=true

RNS Number : 6929A  Porvair PLC  25 September 2025

 

For immediate
release
           25 September 2025

 

 

Porvair plc

("Porvair" or the "Group" or the "Company")

 

Board Changes

Lisa Anson

Lisa Anson has been appointed as Non-Executive Director of the Company with
effect from 1 October 2025.

Lisa is currently Chief Executive Officer of Redx Pharma limited, a UK based,
privately held clinical-stage biotech business; a position she held when Redx
was publicly listed on AIM. In addition, she is a Supervisory Board Member for
Apoplex Medical Technologies GmBH, a private German company and is an elected
Board Member of the UK BioIndustry Association (BIA). She was previously a
Board Member and then Chair at the Association of the British Pharmaceutical
Industry (ABPI).

Lisa's career spans almost 30 years in the pharmaceutical and Biotech industry
including more than twenty years at AstraZeneca Plc. She has extensive global
leadership and commercial experience, including several USA based roles and
most recently was Country President for the UK and Ireland.

On appointment, Lisa will join the Audit Committee, Remuneration Committee and
Nomination Committee of Porvair.

Porvair confirms that there are no further matters in relation to Lisa Anson's
appointment to be disclosed pursuant to the requirements of paragraph 6.4.8 of
the Listing Rules of the UK Listing Authority.

Sally Martin

Having completed 9 years as a Non-Executive Director at Porvair, Sally Martin
will retire from the Board on 4 November 2025.

Sheena Mackay

Following Sally's retirement, Sheena Mackay will be appointed Senior
Independent Director of the Board and the Non-Executive Director responsible
for employee engagement, in addition to her role as Chair of the Remuneration
Committee.

For further information, please contact:

 Porvair plc             +44 (0)1553 765 500
 Hooman Caman Javvi, Chief Executive Officer

 Andrew Douglass, Group Company Secretary

 

 Burson Buchanan      +44 (0)207 466 5000
 Charles Ryland / Stephanie Whitmore

 

 

Notes to editors

 

Porvair plc

Porvair is a group of specialist filtration, laboratory and environmental
technology businesses.  Its businesses design and manufacture a range of
bespoke consumable filtration products that are used in a range of niche
filtration markets.  It operates in three divisions: Aerospace &
Industrial; Laboratory; and Metal Melt Quality.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEZLFLEKLZBBF